We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Reagent Technology Licensed to Olympus Diagnostica

By Labmedica staff writers
Posted on 20 Jan 2005
Print article
A worldwide nonexclusive license to new technology for mixing reagents using surface acoustic waves has been granted to Olympus Diagnostica (Hamburg, Germany) by Advalytix AG (Brunnthal, Germany).

Advalytix pioneered the use of surface acoustic waves (SAW) for the manipulation and agitation of small liquid volumes. The waves induce quasi-chaotic streaming patterns that lead to the efficient agitation of liquids with volumes ranging from several hundred microliters down to a few nanoliters. The agitation method is noninvasive and prevents the risks of cross-contamination and carry-over. SAW technology has been commercially available in a hybridization station of Advalytix called SlideBooster, targeted at the research and development market. Now SAW will be introduced to the diagnostics market.

Olympus Diagnostica will integrate the technology into its product line of routine laboratory analyzers. "This technology will enable Olympus Diagnostica to significantly improve the next generation of analyzers,” noted Dr. Helmut Kohler, CEO of Olympus Diagnostica. Olympus Diagnostica is a systems provider for in vitro diagnostics in clinical chemistry, electrophoresis, and transfusion testing. Under the terms of the agreement, Olympus Diagnostica will provide an upfront payment, milestone payments, and royalties on the sales of instruments.



Related Links:
Olympus Diagnostica
Advalytix
New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit
Automated Blood Typing System
IH-500 NEXT
New
Silver Member
Oncology Molecular Diagnostic Test
BCR-ABL Dx ELITe MGB Kit
New
Centrifuge
Centrifuge 5430/ 5430 R

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.